Diss. (sammanfattning) Linköping : Univ. / Härtill 5 uppsatser.

Diss. (sammanfattning) Stockholm : Karol. inst., 2004. / Härtill 4 uppsatser.

Thesis (Ph.D.)--Virginia Commonwealth University, 2008. / Prepared for: Dept. of Biochemistry. Title from title-page of electronic thesis. Bibliography: leaves 92 - 100.

Yu, Kai Shing. / "November 2010." / Thesis (M.Phil.)--Chinese University of Hong Kong, 2011. / Includes bibliographical references (leaves 103-114). / Abstracts in English and Chinese. / Abstract --- p.2 / 中文摘要 --- p.6 / List of Contents --- p.9 / List of Table --- p.12 / Abbreviation --- p.13 / Acknowledgement --- p.14 / Chapter Chapter 1: --- Introduction --- p.15 / Chapter 1.1 --- Epidemiology of lung cancer --- p.15 / Chapter 1.2 --- Overview of significant prognostic factors for patients with NSCLC --- p.18 / Chapter 1.2.1 --- Tumor related factors --- p.19 / Chapter 1.2.2 --- Patient related factors --- p.21 / Chapter 1.3 --- Overview of significant prognostic factors for SCLC patients --- p.22 / Chapter Chapter 2: --- Literature Review --- p.25 / Chapter 2.1 --- Prevalence of co-morbidity among lung cancer patients --- p.25 / Chapter 2.2 --- Impact of co-morbidity on non small cell lung cancer patients --- p.28 / Chapter 2.3 --- Impact of co-morbidity on small cell lung cancer patients --- p.36 / Chapter 2.4 --- Summary of evidence from literature review --- p.40 / Chapter Chapter 3: --- Aim and Objectives --- p.42 / Chapter 3.1 --- General aim --- p.42 / Chapter 3.2 --- Specific objectives --- p.42 / Chapter 3.3 --- Main hypothesis --- p.42 / Chapter Chapter 4: --- Methodology --- p.43 / Chapter 4.1 --- Research design --- p.43 / Chapter 4.2 --- Study population --- p.43 / Chapter 4.3 --- Sample size estimation --- p.45 / Chapter 4.4 --- Data collection --- p.47 / Chapter 4.4.1 --- Demographic information --- p.47 / Chapter 4.4.2 --- Co-morbidity --- p.51 / Chapter 4.4.3 --- Adverse symptoms --- p.51 / Chapter 4.4.4 --- Disease characteristics --- p.52 / Chapter 4.4.5 --- Baseline laboratory findings --- p.53 / Chapter 4.4.6 --- Treatment data --- p.53 / Chapter 4.4.7 --- Follow up --- p.53 / Chapter 4.5 --- Statistical analyses --- p.54 / Chapter Chapter 5: --- Results --- p.56 / Chapter 5.1 --- Description of cohort --- p.56 / Chapter 5.2 --- Baseline characteristics --- p.58 / Chapter 5.3 --- Symptom presentation --- p.62 / Chapter 5.4 --- Histological characteristics --- p.64 / Chapter 5.5 --- Treatment characteristics --- p.67 / Chapter 5.6 --- Haematological characteristics of study population --- p.69 / Chapter 5.7 --- Prevalence of co-morbidity --- p.71 / Chapter 5.8 --- Overall survival --- p.74 / Chapter 5.8.1 --- Univariate and multivariate survival analysis for SCLC patients --- p.75 / Chapter 5.8.2 --- Univariate and multivariate survival analysis for NSCLC patients --- p.77 / Chapter 5.8.3 --- In-depth analyses for the Impact of co-morbidity on lung cancer survival --- p.79 / Chapter 5.8.4 --- Selected underlying causes of death --- p.84 / Chapter Chapter 6: --- Discussion --- p.85 / Chapter 6.1 --- Prognostic factors --- p.85 / Chapter 6.2 --- Prevalence of co-morbidity --- p.89 / Chapter 6.3 --- Impact of co-morbidity on lung cancer survival --- p.92 / Chapter 6.4 --- Strengths and limitations of this study --- p.97 / Chapter Chapter 7: --- Conclusions --- p.101 / Chapter Chapter 8: --- Implications and Recommendations for medial practice --- p.102 / References --- p.103

Thesis (M.S.)--University of South Florida, 2009. / Title from PDF of title page. Document formatted into pages; contains 56 pages. Includes bibliographical references.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2005. / Härtill 4 uppsatser.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2007. / Härtill 4 uppsatser.

Lin, Hualiang. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2011. / Includes bibliographical references (leaves 140-177). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract also in Chinese.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2007. / Härtill 4 uppsatser.

Metastases pulmonares isoladas de sarcomas de partes moles ocorrem em 20%-50% dos pacientes, e 70% destes pacientes apresentarão doença limitada aos pulmões. A ressecção cirúrgica é bem aceita como tratamento padrão nas metastases de sarcomas de partes moles confinadas aos pulmões, com muitos estudos relatando sobrevida em cinco anos de 305-40%, ssndo que o fator preditor de sobrevida é a ressecção completa. O objetivo deste estudo é determinar as variáveis clínicas e demográficas relacionadas ao tratamento e associadas com a sobrevida global a longo prazo (90 meses) nos pacientes submetidos a metastasectomia pulmonar de sarcomas de partes moles. Uma revisão retrospectiva foi realizada nos pacientes com metastases pulmonares que foram submetidos à toracotomia para ressecção das metástases, após o tratamento do tumor primário. Os dados foram coletados de acordo com as características do tumor primário, dados demográficos, tipo de tratamento e evolução. Pacientes (n=77) com sarcomas de partes moles previamente tratados foram submetidos a um total of 122 toracotomias e 273 nódulos ressecados. O seguimento mediando de todos os pacientes foi de 36.7 meses (variação: 10-138 meses). O índice de complicações pós-peratórias foi 9.1%, e a mortalidade em 30 dias de 0%. A sobrevida global em 90 meses para todos os pacientes foi de 34.7%. A análise multivariada identificou o número de metástases, o intervalo livre de doença, e ressecção completa, como fatores prognósticos independentes para a sobrevida global. Estes resultados confirmam que a metastasectomia pulmonar é um procedimento seguro e com potencial curativo para pacientes com tumors primários tratados. Um grupo seleto de pacientes pode apresentar uma sobrevida a longo prazo interessante após a ressecção pulmonar / Isolated pulmonary metastases from soft tissue sarcomas occur in 20%-50% of these patients, and 70% of these patients will have disease limited only to the lungs. Surgical resection is well accepted as a standard approach to treat metastases from soft tissue sarcomas isolated to the lungs, with many studies reporting overall 5-year survival ranging from 30% to 40%, and the most consistent predictor of survival in these patients is complete resection. The aim of this study is to determine demographics and clinical treatment-related variables associated with long-term (90-month) overall survival in patients with lung metastases undergoing pulmonary metastasectomy from soft tissue sarcomas. A retrospective review was performed of patients who were admitted with lung metastases and underwent thoracotomy for resection, after treatment of the primary tumor. Data were collected regarding primary tumor features, demographics, treatment, and outcome. Patients (n=77) with preview soft tissue sarcomas treated, were submitted to a total of 122 thoracotomies and 273 nodules resected. Median follow-up time of all patients was 36.7 months (range: 10-138 months). The postoperative complication rate was 9.1%, and the 30-day mortality rate was 0%. The 90-month overall survival rate for all patients was 34.7%. Multivariate analysis identified the number of metastases resected, disease-free interval, and complete resection as the independent prognostic factors for overall survival. These results confirm that lung metastasectomy is a safe and potentially curative procedure for patients with treated primary tumors. A select group of patients can achieve long-term survival after lung resection